Zonagen, Inc

Engaged in the development of pharmaceutical products for the reproductive system, including sexual dysfunction, urology, contraception and fertility. In seeking new therapeutic approaches to a wide range of disorders of the reproductive system, Zonagen expects to provide products that address a lifetime of healthcare needs. The Company's focus is on creating futures, beginning with the young adult and continuing well into the senior years. The Company's business strategy is designed to provide a continuing pipeline of proprietary new products that enter development from the company's own research programs as well as through an active acquisition strategy. Establishing marketing collaborations with corporate partners is an integral part of the overall corporate growth strategy. On July 27, 2000, the Company announced that its Board of Directors had made the decision to review strategic alternatives as a result of the previously announced delays associated with the Company's lead product VASOMAX®.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: